IAN Angel Fund, the evergreen fund of the renowned IAN Group, has successfully led a ₹8 crore ($960,000 USD approx.) funding round in Biodimension, a Bengaluru-based life sciences startup specializing in New Approach Methodologies (NAMs) and advanced tissue engineering. The investment round also saw strong participation from existing investor Campus Angels Network, alongside Dr. Sampath Srisailam and notable angel investors such as Mr. Aaryan Baid.
The newly raised capital will be strategically deployed to accelerate advanced product development, expand state-of-the-art laboratory infrastructure in Bengaluru, and strengthen both scientific and commercial teams. Additionally, the funding will drive the commercialization of Biodimension's proprietary tissue models across domestic Indian markets and high-growth international biotechnology hubs.
Addressing a Critical Imperative in Global Drug Discovery
Founded by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension is at the forefront of biofabricating functional human tissue and organoid models. These systems serve as highly predictive, ethical, and human-relevant alternatives to traditional animal testing.
The company's bioengineered solutions help global pharmaceutical, biotechnology, and cosmetic corporations generate precise human data during early-stage trials. This capability enables faster, more reliable decision-making across clinical research, toxicology testing, and product development pipelines.
This investment comes at a pivotal inflection point for the global life sciences industry. Regulators worldwide are accelerating the formal adoption of human-relevant testing technologies. Currently, nearly 90% of experimental drugs fail during human clinical development, despite demonstrating safety and efficacy in animal studies.
This staggering failure rate highlights a massive scientific gap: animal biology frequently fails to replicate human physiological responses. Biodimension addresses this structural bottleneck by offering a highly differentiated testing platform that seamlessly combines deep scientific innovation with cost-effective, localized manufacturing.
Reducing Import Dependency in India's Pharmaceutical Sector
While India has firmly established itself as one of the world's largest pharmaceutical manufacturing and generic drug hubs, the domestic industry remains heavily dependent on imported human tissue models and western pre-clinical testing systems. This reliance introduces supply chain vulnerabilities, high shipping overheads, and lengthy customs delays for local researchers.
Biodimension is directly closing this infrastructure gap. By engineering and manufacturing tissue alternatives locally in Bengaluru, the company provides the Indian pharmaceutical ecosystem with immediate access to cutting-edge research tools. These alternatives comply fully with emerging global regulatory standards while operating at a fraction of the cost of imported systems.
A Comprehensive Portfolio of Engineered Human Tissues
Biodimension has developed a versatile product and service ecosystem designed to replace traditional testing methodologies across multiple industries:
BioDEpi: A reconstructed human epidermis (RHE) model optimized for routine in vitro safety, irritation, and skin toxicity testing.
BioDFT: A full-thickness human skin model that accurately replicates complex human skin biology, including dermal and epidermal layers.
BioDPigma: An advanced, pigmented human skin model specifically engineered for targeted dermatological research, hyperpigmentation studies, and cosmetic ingredient validation.
Pan-Cancer Tumour Microenvironment (TME) Biobank: A sophisticated 3D platform designed to mimic living tumor structures, directly supporting oncology drug discovery and translational cancer research.
BaaS (Bioassay as a Service): An on-demand clinical service model allowing pharmaceutical and cosmetic enterprises to outsource their compliance testing to Biodimension’s validated human-relevant platform.
Executive and Investor Perspectives
"This funding marks a pivotal moment in our journey to redefine drug testing and healthcare innovation. The support from IAN and our co-investors will allow us to accelerate the development and commercialisation of our 3D tumour microenvironment platform and expand our BioDEpi skin model suite. Our goal is to provide pharmaceutical and cosmetic industries with advanced testing platforms that offer more reliable, human-relevant data. This investment is a strong validation of our belief that India is ready to lead in next-generation, human-relevant biology. We are building not just products, but an entire infrastructure for predictive, ethical, and scientifically superior testing, one that will serve the Indian pharma and biotech ecosystem as well as global partners."
— Manojkumar S., Co-Founder & CEO of Biodimension
Capitalizing on a Valued $14 Billion Global Market
The global in vitro toxicology testing market is currently valued at approximately USD 14 billion and continues to exhibit robust, steady growth. This commercial expansion is driven by escalating pharmaceutical R&D investments, tightening international regulatory pressures to phase out animal testing, and the rapid adoption of advanced 3D cell culture technologies.
Biodimension has already established deep research and commercial collaborations with leading pharmaceutical companies, biotechnology firms, academic research institutions, and contract research organizations (CROs) across India and Singapore.
Looking forward, the company plans to systematically expand its Pan-Cancer Tumour Microenvironment Biobank, introduce next-generation oncology and immunotherapy research models, and aggressively scale its Bioassay-as-a-Service platform. Geographically, Biodimension aims to expand its operational footprint across Southeast Asia while building long-term commercial partnerships in Europe, the United States, and Japan.
About Biodimension
Biodimension Technology Pvt. Ltd. is a Bengaluru-based life sciences company specializing in New Approach Methodologies (NAMs) and tissue engineering. The startup develops biofabricated human tissue and organoid models as ethical, human-relevant alternatives to animal testing. Its engineered tissues help pharmaceutical and cosmetic companies accelerate drug discovery and safety testing with more reliable human data, significantly reducing clinical failure rates.
About IAN Angel Fund
IAN Angel Fund is the evergreen fund of the IAN Group. As a SEBI-registered Category I Alternative Investment Fund (AIF), it forms a core component of India's leading early-stage investment platform. Backed by an elite network of approximately 500 investors—including iconic entrepreneurs and global industry leaders—the platform enables founders to raise institutional capital ranging from ₹50 lakh to ₹50 crore as they scale from early-stage development to global commercialization.
